Sanofi teams up with OpenAI and Formation Bio
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently.
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
as it continues on its path to becoming the first biopharma company powered by AI at scale.
UPDATED ON JUNE
May 21 (Reuters) – French drugmaker Sanofi (SASY.PA) announces it partners with artificial intelligence company OpenAI and Formation Bio to boost its drug development projects through the use of Artificial Intelligence.
“This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI. Next generation, first-of-its kind AI model customizations will be an important foundation in our efforts to shape the future of drug development for pharma and for the many patients waiting for innovative treatments.”
Sanofi says in a statement that the partnership with OpenAI allows it to access proprietary data to develop AI models for its biopharma projects. Formation Bio provides additional engineering resources.
Major drugmakers use artificial intelligence to find patients for clinical trials quickly or to reduce the number of people needed to test medicines. This approach speeds up drug development and potentially saves millions of dollars.